Epidemiological findings suggest a relationship between multiple sclerosis (MS) and cardiovascular disease (CVD) risk factors, although the nature of this relationship is not well understood.
Objective:
We used genome-wide association study (GWAS) data to identify shared genetic factors (pleiotropy) between MS and CVD risk factors.
Methods:
Using summary statistics from a large, recent GWAS (total n > 250,000 individuals), we investigated overlap in single nucleotide polymorphisms (SNPs) associated with MS and a number of CVD risk factors including triglycerides (TG), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, body mass index, waist-to-hip ratio, type 2 diabetes, systolic blood pressure, and C-reactive protein level.
Results and conclusion:
Using conditional enrichment plots, we found 30-fold enrichment of MS SNPs for different levels of association with LDL and TG SNPs, with a corresponding reduction in conditional false discovery rate (FDR). We identified 133 pleiotropic loci outside the extended major histocompatibility complex with conditional FDR < 0.01, of which 65 are novel. These pleiotropic loci were located on 21 different chromosomes. Our findings point to overlapping pathobiology between clinically diagnosed MS and cardiovascular risk factors and identify novel common variants associated with increased MS risk.
WensIDalgasUStenagerE. et al. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis—A systematic review. Mult Scler2013; 19: 1556–1564.
LanderES. Initial impact of the sequencing of the human genome. Nature2011; 470: 187–197.
5.
International Multiple Sclerosis Genetics Consortium (IMSGC);BeechamAHPatsopoulosNAXifaraDK. et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet2013; 45: 1353–1360.
6.
SawcerSHellenthalGPirinenM. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature2011; 476: 214–219.
7.
AndreassenOHarboHWangY. et al. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: Differential involvement of immune-related gene loci. Mol Psychiatry2015; 20: 207–214.
8.
AndreassenOADjurovicSThompsonWK. et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet2013; 92: 197–209.
9.
AndreassenOAMcEvoyLKThompsonWK. et al. Identifying common genetic variants in blood pressure due to polygenic pleiotropy with associated phenotypes. Hypertension2014; 63: 819–826.
10.
AndreassenOAThompsonWKDaleAM. Boosting the power of schizophrenia genetics by leveraging new statistical tools. Schizophr Bull2014; 40: 13–17.
11.
AndreassenOAThompsonWKSchorkAJ. et al. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet2013; 9: e1003455.
12.
LiuJZHovJRFolseraasT. et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet2013; 45: 670–675.
13.
AndreassenOAZuberVThompsonWK. et al. Shared common variants in prostate cancer and blood lipids. Int J Epidemiol2014; 43: 1205–1214.
14.
DesikanRSSchorkAJWangY. et al. Polygenic overlap between C-reactive protein, plasma lipids and Alzheimer’s disease. Circulation2015; 131: 2061–2069.
15.
DesikanRSchorkAJWangY. et al. Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus. Mol Psychiatry2015; 20: 1588–1595.
16.
The International Consortium For Blood Pressure Genome-Wide Association Studies; EhretGBMunroePBRiceKM. et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature2011; 478: 103–109.
17.
TeslovichTMMusunuruKSmithAV. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature2010; 466: 707–713.
18.
VoightBFScottLJSteinthorsdottirV. et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet2010; 42: 579–589.
19.
SpeliotesEKWillerCJBerndtSI. et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet2010; 42: 937–948.
20.
HeidIMJacksonAURandallJC. et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet2010; 42: 949–960.
21.
DehghanADupuisJBarbalicM. et al. Meta-analysis of genome-wide association studies in > 80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation2011; 123: 731–738.
22.
NicklesDChenHPLiMM. et al. Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum Mol Genet2013; 22(20): 194–205.
23.
MiHMuruganujanACasagrandeJT. et al. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc2013; 8: 1551–1566.
24.
Joshi-TopeGGillespieMVastrikI. et al. Reactome: A knowledgebase of biological pathways. Nucleic Acids Res2005; 33: D428–D432.
25.
ChenG-BLeeSHBrionM-JA. et al. Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. Hum Mol Genet2014; 23: 4710–4720.
26.
LeeSHYangJGoddardME. et al. Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. Bioinformatics2012; 28: 2540–2542.
27.
Bulik-SullivanBKLohP-RFinucaneHK. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet2015; 47: 291–295.
28.
SchorkAJWangYThompsonWK. et al. New statistical approaches exploit the polygenic architecture of schizophrenia-implications for the underlying neurobiology. Curr Opin Neurobiol2016; 36: 89–98.
29.
HemmerBKerschensteinerMKornT. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol2015; 14: 406–419.
30.
MarchantDJBoydJHLinDC. et al. Inflammation in myocardial diseases. Circ Res2012; 110: 126–144.
31.
HanssonGKHermanssonA. The immune system in atherosclerosis. Nat Immunol2011; 12: 204–212.
32.
NorataGDPirilloAAmmiratiE. et al. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis2012; 220: 11–21.
33.
ManettiMGuiducciSIbba-ManneschiL. et al. Mechanisms in the loss of capillaries in systemic sclerosis: Angiogenesis versus vasculogenesis. J Cell Mol Med2010; 14: 1241–1254.
34.
D’haeseleerMCambronMVanopdenboschL. et al. Vascular aspects of multiple sclerosis. Lancet Neurol2011; 10: 657–666.
35.
MungerKLBentzenJLaursenB. et al. Childhood body mass index and multiple sclerosis risk: A long-term cohort study. Mult Scler2013; 19: 1323–1329.
36.
CorrealeJAguirreMEBFarezM. Body mass index and multiple sclerosis risk. The role of leptin (S24.004). Neurology2014; 82. no. 10 Supplement S24.004xt
37.
NicholsTBrettMAnderssonJ. et al. Valid conjunction inference with the minimum statistic. Neuroimage2005; 25: 653–660.
38.
DevlinBRoederK. Genomic control for association studies. Biometrics1999; 55: 997–1004.
